Forschung und Berichte in den medizinischen Wissenschaften

Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy

Abstract

Jason Katz*

Cystic fibrosis transmembrane conductance controller modulator treatment have brought about longer futures, yet pneumonic intensifications stay a main source of grimness. The main treatment is antibiotics given intravenously, but getting enough of them is still hard. The impact of restorative medication observing of beta-lactams on intensifications and lung capability has not been contemplated. From 32 cystic fibrosis patients admitted for exacerbations, demographics, antibiotic regimens, forced expiratory volume 1 second, and exacerbation history were gathered. All patients had Pseudomonas aeruginosa colonization, were treated with CFTR for at least a year, and were followed up every three months. Before and after therapeutic drug monitoring, plasma concentrations, FEV1, and exacerbation history were gathered. This included using liquid chromatography with mass spectrometry to measure cefepime and piperacillin tazobactam's peak and trough plasma concentrations. T-test and Mann-Whitney U test were utilized to look at medians/method for FEV1 and pneumonic intensifications pre and post-TDM as well as free box to-least inhibitory focus proportion.